 |
Asthmatx
Mountain View, CA |
|
Asthmatx has developed and patented a radiofrequency catheter
and controller for reducing the amount of airway smooth
muscle tissue in the lungs of asthma patients. This procedure
improves the pulmonary function of moderate and severe
asthmatics. Over 13 million adults in the U.S. suffer
from asthma, roughly 10% or 1.3 million have been diagnosed
with severe asthma.
|
 |
Hansen
Medical
Mountain View, CA |
Invested: November
2005
Nasdaq: HNSN |
Hansen has developed a robotic catheter control system
for precise catheter navigation and control within the
chambers of the heart. The first application of the Hansen
robotic system will be to enable the RF ablation of atrial
fibrillation (AF) arrhythmias in the left atrium. There
are 2.2 million US patients suffering from AF with an
annual incidence of 160K patients. Drug therapy is inadequate,
open surgical procedures have high morbidity rates, and
unguided catheter ablation lacks efficacy. Hansen’s
robotic technology provides precise guidance and control
of the RF ablation catheter thereby enabling more effective
and less time consuming AF procedures. Hansen’s robotic
system will be applied to other cardiac procedures in
the future.
|
|
Peptimmune
Cambridge, MA
|
Invested: March 2003
|
Peptimmune is a biotechnology company which develops
specific immunotherapies for the treatment of autoimmune
and allergic diseases. The company is using its knowledge
of the molecular details of immune cell regulation to
create a new generation of potentially safer and more
effective drugs for immune disorders.
|
|
Vesalius
Ventures
Houston, TX
|
Invested: June
2002
|
Vesalius Ventures is a telemedicine accelerator formed by former NASA astronaut and physician Bernard Harris. During its three-year charter, Vesalius will identify business opportunities from throughout the fields of telemedicine, medical informatics, and technology for the purpose of delivering health care. Vesalius will arrange initial financing and provide start-up management talent to nurture young portfolio companies and bring them to market faster... "Accelerating the future of Medicine".
|
|
BioSeek
Burlingame, CA
|
Invested: January
2002
|
Bioseek is a provider of postgenomic target validation
and drug development. The company addresses the need for
more efficient and predictive drug discovery technologies
and is focused on applying its proprietary technologies
to the identification, validation, and commercialization
of therapeutic targets and pharmaceuticals. Bioseek's
initial customers/partners will be biotechnology
and pharmaceutical companies.
|
|
Xeotron
Houston, TX
|
Invested: May
2001
Acquired by Invitrogen
|
Xeotron is a developer and manufacturer of platform independent,
high-performance biochips. The company's advanced chips
set new standards because they are free of the problems
of expense, time, and versatility experienced by users
of chips made by other companies. Customers include biology
and pharmaceutical research institutions and corporations.
|
|
Phormax
Sunnyvale, CA
|
Invested: December
2000
Acquired by Alara
|
Phormax develops high-performance, cost-effective,
computed radiography imaging systems. These products enable
ease of access to images and improve communications between
providers, resulting in improved efficiencies, faster
access to diagnoses, fewer lost films, and improved patient
care. Target customers include hospitals, outpatient imaging
centers, surgery centers, and rehabilitation centers,
private physician offices, clinics, and the military.
|
 |
TissueLink
Medical
Dover, NH
|
Invested: August
1999
|
TissueLink Medical is a developer and distributor
of innovative medical devices that are transforming current
surgical procedures. The company’s technology eliminates
the need for multiple technologies with the potential
to reduce operating room and patient recovery time by
enabling precise coagulation and cutting, with no excess
damage to tissue. These devices will be used in general
and thoracic surgical procedures.
|
|
Artemis
Medical
Hayward, CA |
Invested: July 1999
Acquired by Johnson & Johnson
NYSE: JNJ
|
Artemis Medical designs and develops
innovative medical devices to improve earlier diagnosis
and treatment of cancer. Its technologies provide physicians
minimally-invasive alternatives to open surgical techniques
used in cancer surgery today. These products will serve
the needs of patients, physicians, and healthcare payers.
|
Back to Top
|
Kodiak
Technologies
Houston, TX
|
Invested: June
1999
|
Kodiak Technologies is a developer and distributor
of innovative and technologically advanced shipping containers
used in the delivery of temperature sensitive products.
The company offers a turnkey solution including a full-service
logistics management service and a web-enabled information
system that allows for 24x7 ordering, shipment tracking
and temperature monitoring. The products are used in commercial,
industrial, and medical markets.
|
 |
Eunoe
(formerly CS Fluids)
Pleasanton, CA |
Invested: October
1998
Acquired by Integra Life Sciences
|
Eunoe has developed and is testing a pioneering, device-based
treatment for Alzheimer's disease. The device is a cerebrospinal
fluid shunt that is believed to facilitate the clearance
of neurotoxins that may be significant in the progression
of Alzheimer's disease. The principal market consists
of the 27 million patients worldwide with Alzheimer’s
disease.
|
 |
Sontra
Medical
Cambridge, MA
|
Invested: September
1998
NasdaqSC: SONT.PK
Acquired by Echo Therapeutics |
Sontra Medical, Inc. is medical device company
developing ultrasound-powered methods for transdermal
drug delivery of large molecules and diagnostics. The
system is being designed to provide a convenient and painless
method of enhancing transport of molecules through human
skin. Initial areas of application are transdermal delivery
of large molecules for such applications as diabetes,
hormone therapy, pain controls, etc., non-evasive testing
of blood analytes such as glucose for diabetes control
is also possible. insulin for patients with diabetes.
The worldwide market is comprised of approximately 125
million individuals.
|
 |
HemoSense
Milpitas, CA |
Invested: November
1997
|
HemoSense develops portable, handheld analyzers that test
the clotting time of whole blood via Prothrombin Time
(PT) measurement. These analyzers consist of a low-cost
meter and disposable test strips that can be used at home
as well as in a physician’s office or clinic setting.
They offer a convenient and cost-efficient self-testing
solution for patients taking anti-coagulants. The company
will target physicians’ offices and anticoagulation
clinics.
|
Back to Top
 |
EndoVasix
Belmont, CA |
Invested: October
1996
|
Endovasix is a developer of a proprietary technology used
to treat acute cerebral arterial clots that cause strokes.
Its initial offering is a technology that breaks apart
an acute clot in a more effective fashion than thrombolytic
drugs, and that can be used adjunctively with a wide array
of interventional cardiology and radiology procedures.
The target market includes Vascular Neurologists, Interventional
Radiologists, NeuroRadiologists, and Cardiologists and
Endovascular Surgeons and Neurosurgeons who treat patients
who have experienced an occlusive stroke, coronary artery
disease, or a peripheral stroke.
|
|
CryoGen
San Diego, CA |
Invested:
October 1995
Acquired by American Medical Systems
NasdaqNM: AMMD
|
Cryogen is the developer
and provider of a cost-effective cryotherapy device
and system to treat excessive uterine bleeding. The
company's initial product is designed to reduce or eliminate
the symptoms associated with excessive menstrual bleeding
and to provide an alternative to hysterectomy. This
is accomplished by using cryoablation which freezes
and destroys tissue at extremely low temperatures. The
customers include gynecologists, surgery centers, and
hospitals.
|
|
Myelos
Corporation
San Diego, CA
|
Invested: May
1995
Acquired by Savient Pharmaceuticals
NasdaqNM: SVNT
|
Myelos has developed peptide-based therapeutics
for nervous system disorders. These small peptides are
far more cost-effective to manufacture than full-length
recombinant proteins and may be engineered as mimetics
to enhance drug efficacy, stability and bioavailability.
The target market are physicians treating patients with
pain syndromes and a broad range of peripheral neuropathies,
including those associated with diabetes, chemotherapy,
and nerve injury.
|
 |
CardioGenesis
Foothill Ranch, CA |
Invested: November
1993
Acquired by Eclipse Surgical
Nasdaq: CGCP.PK |
CardioGenesis is the leader in transmycardioal revascularization.
This novel minimally-invasive laser based technology offers
an option for patients who are not candidates for open
heart bypass surgery or percutaneous transluminal coronary
angioplasty (PTCA) as it does not rely on re-establishing
blood flow through the coronary arteries by conventional
means such as coronary artery bypass surgery CABG) or
PTCA. There are approximately 30,000 patients who could
be candidates for TMR.
|
Back to Top
 |
Indigo
Medical
Palo Alto, CA |
Invested: October
1991
Acquired by Johnson & Johnson
NYSE: JNJ |
Indigo Medical is a producer of devices for the urology
market. The devices are minimally or non-invasive and
allow Benign Prostatic Hyperplasia treatment to take place
in a private office setting as opposed to a hospital or
an ambulatory surgical center, thereby reducing the costs
of treatment.
|
 |
EndoSonics
Sweden |
Invested: October
1984
Acquired by Jomed
|
EndoSonics is an intraluminal ultrasound technology
used for visual imaging in artery functions. Its products
enhance the effectiveness of the diagnosis and treatment
of cardiovascular disease by aiding cardiologists in identifying
diseased arteries, selecting proper treatment, positioning
a therapeutic device, treating diseased sites, and assessing
results of treatment.
|
 |
Mycogen
Indianapolis, IN
|
Invested: January
1983
Acquired by Dow Chemical
NYSE: DOW |
Mycogen develops biopesticide products using biotechnology
and genetic engineering techniques. The company's products
are based on microorganisms such as fungi and bacteria
which have specific toxic activity against target weeds
and insects and are not harmful to closely related plant
species or beneficial insects. The company targets chemical
and agricultural industries.
|
|
EndoTherapeutics
Norwalk, CT |
Invested: October
1984
Acquired by U.S. Surgical/Tyco
NYSE: TYC |
Endo Therapeutics is a producer of in vivo therapeutic
systems and surgical instruments. Included in its product
offerings is the disposable trocar for laparoscopy procedures,
a port of entry device which allows a telescope to be
inserted into the abdomen.
|
Back to Top
about
vanguard | team
| portfolio | for
entrepreneurs | news
| contact us
Copyright © 2002 Vanguard Ventures
|
